Humanised antibody-based drug developer Harbour BioMed has now raised $210m altogether following a series B-plus round featuring Zhejiang University Future Capital.
US-based immuno-oncology and inflammatory disease therapy developer Harbour BioMed completed a $75m series B-plus round yesterday featuring university-founded venture unit Zhejiang University Future Capital.
Legend Capital, the venture capital firm established by conglomerate Legend Holdings, participated in the round together with conglomerate SK Group.
The round also included Greater Bay Area Fund, an investment partnership backed indirectly by the governments of Russia, China and Guangdong province, as well as Singaporean sovereign wealth fund GIC.
Advantech Capital, Efung…